| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Unit of Internal Medicine, Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy
Institute of Clinical Chemistry, University of Verona, Verona, Italy
Section of Biology and Genetics, Department of Mother and Child and Biology–Genetics, University of Verona, Verona, Italy
1 To whom correspondence should be addressed. e-mail: oliviero.olivieri{at}univr.it
Apolipoprotein C-III (apoC-III) is a marker of triglyceride (TG)-rich lipoproteins, which are often increased in metabolic syndrome (MS). The T-455C polymorphism in the insulin-responsive element of the APOC3 gene influences TG and apoC-III levels. To evaluate the contribution of apoC-III levels and T-455C polymorphisms in the coronary artery disease (CAD) risk of MS patients, we studied 873 patients, 549 with CAD and 251 with normal coronary arteries. Patients were classified also as having or not having MS (MS, n = 270; MS-free, n = 603). Lipids, insulin, apolipoprotein levels, and APOC3 T-455C genotypes were evaluated. ApoC-III levels were significantly increased in MS patients, and the probability of having MS was correlated with increasing quartiles of apoC-III levels. MS patients with CAD had significantly higher apoC-III levels than did CAD-free MS patients. The carriership for the -455C variant multiplied the probability of CAD in MS in an allele-specific way and was associated with increased apoC-III and TG levels. Obesity was less frequent in MS carriers of the -455C allele than in MS noncarriers (21.6% vs. 34.8%, P < 0.05).
In conclusion, apoC-III-rich lipoprotein metabolism and the APOC3 polymorphism have relevant impacts on the CAD risk of MS patents.
Supplementary key words apolipoproteins • apoC-III • coronary disease • genes • lipids
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  E. A Ruiz-Narvaez, F. M Sacks, and H. Campos Abdominal obesity and hyperglycemia mask the effect of a common APOC3 haplotype on the risk of myocardial infarction Am. J. Clinical Nutrition, June 1, 2008; 87(6): 1932 - 1938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sookoian and C. J. Pirola Review: Genetics of the cardiometabolic syndrome: new insights and therapeutic implications Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 37 - 47. [Abstract] [PDF]
|
|
|
|
 |
|
 S. M. Grundy Gamma-Glutamyl Transferase: Another Biomarker for Metabolic Syndrome and Cardiovascular Risk Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 4 - 7. [Full Text] [PDF]
|
|
|
|
|
|
A. Kawakami, M. Aikawa, N. Nitta, M. Yoshida, P. Libby, and F. M. Sacks Apolipoprotein CIII-Induced THP-1 Cell Adhesion to Endothelial Cells Involves Pertussis Toxin-Sensitive G Protein- and Protein Kinase C{alpha}-Mediated Nuclear Factor-{kappa}B Activation Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 219 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Ruiz-Narvaez, Y. Yang, Y. Nakanishi, J. Kirchdorfer, and H. Campos APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica J. Lipid Res., December 1, 2005; 46(12): 2605 - 2613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bozzini, D. Girelli, O. Olivieri, N. Martinelli, A. Bassi, G. De Matteis, I. Tenuti, V. Lotto, S. Friso, F. Pizzolo, et al. Prevalence of Body Iron Excess in the Metabolic Syndrome Diabetes Care, August 1, 2005; 28(8): 2061 - 2063. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Banning Obesity: pathophysiology and treatment The Journal of the Royal Society for the Promotion of Health, July 1, 2005; 125(4): 163 - 167. [Abstract] [PDF]
|
|
|
|
|
|
G. Gerritsen, P. C. N. Rensen, K. E. Kypreos, V. I. Zannis, L. M. Havekes, and K. Willems van Dijk ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression J. Lipid Res., July 1, 2005; 46(7): 1466 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Genoux, H. Dehondt, A. Helleboid-Chapman, C. Duhem, D. W. Hum, G. Martin, L. A. Pennacchio, B. Staels, J. Fruchart-Najib, and J.-C. Fruchart Transcriptional Regulation of Apolipoprotein A5 Gene Expression by the Nuclear Receptor ROR{alpha} Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1186 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Shearer, J. W. Newman, B. D. Hammock, and G. A. Kaysen Graded Effects of Proteinuria on HDL Structure in Nephrotic Rats J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1309 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Guettier, A. Georgopoulos, M. Y. Tsai, V. Radha, S. Shanthirani, R. Deepa, M. Gross, G. Rao, and V. Mohan Polymorphisms in the Fatty Acid-Binding Protein 2 and Apolipoprotein C-III Genes Are Associated with the Metabolic Syndrome and Dyslipidemia in a South Indian Population J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1705 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Olivieri, N. Martinelli, M. Sandri, A. Bassi, P. Guarini, E. Trabetti, F. Pizzolo, D. Girelli, S. Friso, P. F. Pignatti, et al. Apolipoprotein C-III, n-3 Polyunsaturated Fatty Acids, and "Insulin-Resistant" T-455C APOC3 Gene Polymorphism in Heart Disease Patients: Example of Gene-Diet Interaction Clin. Chem., February 1, 2005; 51(2): 360 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.C. Shoulders, E.L. Jones, and R.P. Naoumova Genetics of familial combined hyperlipidemia and risk of coronary heart disease Hum. Mol. Genet., April 1, 2004; 13(90001): R149 - 160. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
